
Veeva Systems (VEEV) Stock Forecast & Price Target
Veeva Systems (VEEV) Analyst Ratings
Bulls say
Veeva Systems is forecasted to generate approximately $1,252 million in subscription revenues from its commercial segment in FY26, reflecting a slight increase over previous expectations, while the R&D segment is expected to yield $1,420 million, indicating similar positive momentum. The company reported a total revenue increase of 16% year-over-year, surpassing estimates thanks to stronger-than-anticipated subscription and professional service revenues, which resulted in a notable 150 basis point expansion in non-GAAP operating margin to 45%. Subscription revenue growth reached 17.5% year-over-year, significantly exceeding consensus estimates, driven by robust demand in both commercial and R&D solutions, suggesting continued strength across Veeva’s product offerings.
Bears say
Veeva Systems is currently trading at approximately 9x EV/NTM revenues, which is below its historical average of 10.5x, indicating potential valuation concerns. There is a risk of declining demand for Veeva's solutions if their cost-effectiveness and value proposition diminish, which could lead to subscription cancellations and negatively impact revenue. Furthermore, Veeva's dependence on the financial health of its clients poses a significant risk, particularly given the challenges facing large pharmaceutical companies and limited funding for smaller biotech firms in the current macroeconomic environment.
This aggregate rating is based on analysts' research of Veeva Systems and is not a guaranteed prediction by Public.com or investment advice.
Veeva Systems (VEEV) Analyst Forecast & Price Prediction
Start investing in Veeva Systems (VEEV)
Order type
Buy in
Order amount
Est. shares
0 shares